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Tamoxifen is the standard first-line endocrine therapy for breast cancer, but recent data indicate that it is likely to be replaced by the
effective aromatase inhibitors (AIs), in both the metastatic and adjuvant settings. Aromatase inhibitors induce complete oestrogen
deprivation that leads to clinically significant bone loss. Several ongoing or planned trials combine AIs with bisphosphonates, even
more so that recent data reveal that clodronate may reduce the incidence of bone metastases and prolong survival in the adjuvant
setting. Bisphosphonates can inhibit breast cancer cell growth in vitro, but they have never been studied in steroid-free medium (SFM),
an in vitro environment that mimics the effects of AIs in vivo. Quite surprisingly, in SFM, clodronate stimulated MCF-7 cell growth in a
time- and dose-dependent manner by up to two-fold (crystal violet staining assay), whereas it had no mitogenic activity in complete
medium. The bisphosphonate similarly increased the proliferation of IBEP-2 cells, which also express a functional oestrogen receptor
(ER), while it weakly inhibited the growth of the ER-negative MDA-MB-231 cells. Expectedly, 17b-oestradiol stimulated the growth of
MCF-7 and IBEP-2 cells cultured in SFM, and had no effect on MDA-MB-231 cells. Moreover, partial (4-OH-tamoxifen) and pure
antioestrogens (fulvestrant, ICI 182,780), in combination with clodronate, completely suppressed the mitogenic effect of the
bisphosphonate, suggesting that it was mediated by an activation of ER. In accordance with this view, clodronate induced ER
downregulation, weakly increased progesterone receptor expression, and stimulated the transcription of an oestrogen-responsive
reporter gene. In conclusion, we report a previously unknown stimulatory effect of clodronate on MCF-7 cells grown in SFM, in vitro
conditions that are potentially relevant to the use of AIs for breast cancer. Moreover, our data suggest that ER is involved in these
effects of clodronate on cancer cell growth.
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Breast cancer is the most prominent malignant neoplasm in
women, at least in economically developed Western countries.
Tamoxifen stands as the standard first-line endocrine therapy for
female patients with breast carcinoma expressing oestrogen
receptor alpha (ER), who represent the majority of breast cancer
cases. Tamoxifen inhibits the growth of breast tumors by
competitively antagonising oestrogen effect on cognate receptors
(Bardon et al, 1984). It also has partial agonist (i.e. oestrogenic)
activity which can be beneficial since it prevents bone loss in
postmenopausal women (Love et al, 1994; Powles et al, 1996).
A novel approach for the hormonal therapy of breast carcinoma
relies on the use of aromatase inhibitors (AIs) in place of tamoxifen.
AIs markedly suppress plasma oestrogen level in postmenopausal
women by inhibiting or inactivating aromatase enzymes respon-
sible for the synthesis of oestrogen from androgenic substrates
(Brodie and Njar, 2000). They also markedly inhibit intratumoral
aromatase activity present in the majority of breast cancers
(Harper-Wynne and Dowsett, 2001; Miller et al, 2001).
Last generation nonsteroidal AIs, such as letrozole (Femara
s)
and anastrozole (Arimidex
s), are widely recommended as second-
line hormonal agents for postmenopausal breast cancer patients
(Goss and Strasser, 2001) and they have recently proven to be
superior to tamoxifen as first-line treatment for advanced disease
(Bonneterre et al, 2000; Nabholtz et al, 2000; Mouridsen et al,
2001) and, even more importantly, in the adjuvant setting as well
(Baum et al, 2002). Thus, AIs are bound to progressively replace
tamoxifen for the first-line treatment of postmenopausal patients
with ER-positive cancers (Smith and Dowsett, 2003).
Nevertheless, the risk of osteoporotic fractures is likely to
increase with the use of AIs since the maintenance of bone density
partly depends on oestrogen, even in postmenopausal women. On
the other hand, tamoxifen reduces bone mineral loss through its
weak agonist effect, at least in postmenopausal women (Powles
et al, 1996). Short-term use of letrozole has been shown to be
associated with an increase in bone resorption markers in plasma
and urine (Harper-Wynne et al, 2002; Heshmati et al, 2002) and
adjuvant therapy with anastrozole is associated with a higher
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yincidence of fractures than adjuvant therapy with tamoxifen
(Boccardo et al, 2001; Baum et al, 2002).
It should be possible to prevent bone demineralization
associated with oestrogen deprivation therapy by combining the
latter with the use of bisphosphonates (Cummings et al, 1998).
Bisphosphonates are indeed potent inhibitors of osteoclasts
and represent the reference therapy for the management of
postmenopausal osteoporosis (Fleisch, 2003). Moreover, many
studies indicate that they prevent the development of metastatic
bone diseases in animals (Yoneda et al, 2000). A few human trials
have already been performed to evaluate oral clodronate in this
setting. Although the clinical usefulness of this compound in the
adjuvant treatment of breast cancer remains somewhat contro-
versial (Diel et al, 1998; Saarto et al, 2001; Coleman, 2003), the
largest trial so far has shown that clodronate can decrease
the incidence of bone metastasis and prolong survival (Powles
et al, 2002). Several trials are currently in progress or planned
to disclose possible combined effect of AIs and various
bisphosphonates in the treatment of breast cancers, with
the prospect of preventing bone mineral loss and reducing the
incidence of bone metastasis.
Bisphosphonates are also able to inhibit breast cancer cell
growth in vitro (for a review, see Neville-Webbe et al, 2002).
However, all studies reported so far were performed in steroid-
containing medium. The present work has investigated the effects
of clodronate on the growth of the ER-positive MCF-7 breast
cancer cell line cultured in steroid-free medium (SFM) in order to
mimic the effect of AIs in vivo. We have also analysed the effect of
clodronate in combination with ER agonist and antagonists, with
particular emphasis on ER expression and activity.
MATERIAL AND METHODS
Cell culture conditions
The ER-positive MCF-7 breast cancer cell line (ATCC HTB-22) was
initially obtained in 1977 from the Michigan Cancer Foundation
(Detroit, MI, USA). IBEP-2 cell line was previously established in
our laboratory from a pleural effusion due to metastatic breast
carcinoma (Siwek et al, 1998) and also expresses functional ER.
MDA-MB-231 breast carcinoma cells (ATCC HTB-26) lack ER
expression.
All plastic flasks, dishes and multiwell plates for cell culture were
obtained from Nunct (Naperville, IL, USA). Cells were cultured at
371C in a humidified 95% air and 5% CO2 atmosphere.
For routine maintenance, cells were cultured in 75-cm
2 flasks
containing Eagle’s minimum essential medium (MEM) with
Phenol Red, supplemented with 10% heat-inactivated fetal calf
serum (FCS), and containing standard concentrations of L-
glutamine, penicillin and streptomycin (Gibco BRL, Life Technol-
ogies, Merelbeke, Belgium). Cells were harvested by trypsinisation
(0.1% trypsin – 0.02% EDTA) and subcultured twice a week.
For all experiments, cells were plated in SFM (day 0) consisting
of RPMI Medium 1640 without Phenol Red (Gibco BRL, Life
Technologies, Merelbeke, Belgium), supplemented with 10%
charcoal-stripped FCS as previously described (Devleeschouwer
et al, 1987). At day 1, the seeding medium was replaced by fresh
SFM containing clodronate (gift from Roche Diagnostics GmbH,
Mannheim, Germany), 17b-oestradiol (E2; Sigma, St Louis, MO,
USA), 4-hydroxy-tamoxifen (4-OH-TAM; Sigma, St Louis, MO,
USA) fulvestrant (ICI 182,780; Tocris, Bristol, UK) at concentra-
tions specified in ‘Results’. In control cultures, drug solution was
replaced by an equivalent amount of vehicle. Treatment lasted
from 1 to 3 days.
MVLN cells (generously provided by Dr M Pons, INSERM U58,
Monpellier, France) are MCF-7 cells stably transfected with the
oestrogen-response element cloned upstream the luciferase
reporter gene (Demirpence et al, 1993). They were cultured in
the same conditions as that used for MCF-7 cells.
Crystal violet staining
Cell number was assessed indirectly by staining with crystal violet
dye, since the total amount of cell-bound dye is proportional to cell
number (Lee et al, 2001). Cancer cells were seeded in 96-well plates
(density 5000 cellswell
 1) in SFM or complete medium, and
cultured for 24h. Cells were then exposed to clodronate, E2,
antioestrogens or vehicle as described in ‘Results’. After incuba-
tion, the medium was removed and cells were gently rinsed with
PBS. Cells were fixed with 1% glutaraldehyde/PBS for 15min and
stained with crystal violet (0.1% w/v in dd H2O). Cell surfaces were
destained under slightly floating tap water for 15min and
subsequently lysed with 0.2% Triton X-100 (v/v in dd H2O). The
absorbance was measured at 550nm using a Microplate Auto-
reader EL309 (BIO-TEK Instruments). Blanks (wells containing
medium alone) were processed in parallel, and their values were
subtracted from those of the sample plates.
Western blot analysis (ER and PgR)
Oestrogen receptor (ER) and progesterone receptor (PgR) amounts
per milligram proteins were determined by Western blotting. Cells
were plated in 60-cm
2 Petri dishes (density 10000 cellscm
 2)i n
SFM and cultured for 24h. After incubation with clodronate, E2 or
vehicle as specified in ‘Results’, cell cultures were rinsed twice with
tris-buffered saline (TBS, 50mM Tris-HCl pH 7.5 and 150mM
NaCl) and harvested using 500ml lysis buffer (TBS, 0.5% sodium
deoxycholate, 1% Nonidet P-40, 0.1% SDS, 50mM NaF, 0.1mM
Na3VO4 and 5mM EDTA) with freshly added proteolysis inhibi-
tors. Total cell lysates were mixed with standard electrophoresis
sample buffer. Denatured samples (20 and 40mg of cellular
proteins for ER and PgR assays, respectively) were subjected to
SDS–PAGE under reducing conditions. Proteins were subse-
quently electrotransferred onto a nitrocellulose membrane (Amer-
sham Pharmacia Biotech, Roosendaal, The Netherlands). The
membrane was then incubated for 3h at room temperature in a
blot solution (10mM Tris-HCl pH 8, 150mM NaCl, 0.05% Tween 20
and 7% skimmed milk) to block nonspecific binding, then
incubated overnight at 41C in a fresh blot solution containing
polyclonal rabbit anti-human ERa antibody (HC-20, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) diluted 1:5000 or mono-
clonal mouse anti-human PgR (A/B isoforms) antibody (NCL-
PGR-AB, Novocastra Laboratories, Newcastle upon Tyne, UK)
diluted 1:500. Immunoblots were then incubated for 2h at room
temperature in a blot solution containing peroxidase-labelled
donkey anti-rabbit IgG antibody (1:5000) or peroxidase-labelled
sheep anti-mouse IgG antibody (1:5000) (Amersham Pharmacia
Biotech, Roosendaal, The Netherlands), depending on primary
used antibody. The bound peroxidase activity was revealed using
the Lumi-Light Western Blotting Substrate (Roche Diagnostics
GmbH, Mannheim, Germany). The immunoreactive band intensity
was estimated using a computer-assisted gel scanning densit-
ometer (GS-710 Callibrated Imaging Densitometer) and Quantity
One software, both from Bio-Rad (Hercules, CA, USA).
Luciferase induction assay
MVLN cells were used to study the transcriptional activity of ER by
determining ER-induced luciferase activity (Demirpence et al,
1993) using the Luciferase Assay System from Promega (Madison,
WI, USA). Cells were plated in six-well plates (density 100000
cellswell
 1) in SFM and were cultured for 72h. At the end of
treatment with clodronate, E2, antioestrogens or vehicle as
described in ‘Results’, the medium was removed and the cell
monolayers rinsed twice with PBS. A minimal volume (250ml) of a
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culture was maintained under mild agitation for 20min to extract
luciferase. Detergent-lysed cells were scraped and suspensions
were clarified by centrifugation for 5min at 10000g. Finally, 20ml
of extracts were mixed at room temperature with 100mlo fa
luciferase reactant medium (Promega E151A/E152A) prepared
according to the manufacturer’s protocol. Luminescence was
measured in a Berthold luminometer (Lumat LB 9507). Luciferase
induction was expressed in arbitary units (relative luciferase units,
RLU) calculated per mg of protein and data are given in percent of
mean value obtained from untreated cells.
Protein determination
Protein concentrations in total cell lysates obtained by detergent
extraction were determined by the BCA Protein Assay (Pierce,
Rockford, IL, USA) using bovine serum albumin (BSA) as
standard.
Statistical analysis
Data are reported as means7s.d. Statistical analysis was
performed using analysis of variance (ANOVA) with a statistical
significance level arbitrarily set at 0.05 (Fisher’s PLSD) (StatView
version 4.02).
RESULTS
Clodronate-induced stimulation of MCF-7 cell growth
in SFM
MCF-7 cells were cultured in SFM for 24h before additional
exposure to 10
 4 M clodronate or 10
 9 M 17b-oestradiol (E2) during
72h in order to assess cell growth. In these steroid-free culture
conditions, clodronate stimulated cell proliferation as evidenced
by a marked increase in cell number by 51721% (mean7s.d.,
Po0.05) compared with controls (Figure 1). As expected, E2 also
exerted a growth stimulatory effect (60720%, Po0.05) under
similar conditions. By contrast, neither clodronate nor E2
stimulated MCF-7 cell growth in medium supplemented with
normal, steroid-containing serum (complete medium) (Figure 1).
These results suggest that clodronate exerts a mitogenic activity on
ER-positive breast cancer cells when the latter are cultured in
absence of oestrogens.
Time-course experiments performed over 72h indicated that
clodronate increased cell proliferation in a time-dependent
manner similar to what is seen with E2 (Figure 2). Enhancement
of cell growth was significant (Po0.05) after 48h of exposure to
either compound.
The dose–response relationships characterising the mitogenic
effect of E2 or clodronate on hormone-deprived MCF-7 cells after
72h of culture are illustrated in Figure 3 (upper panel). Clodronate
(10
 7–10
 3 M) induced a dose-dependent response with a maximal
stimulation of about two-fold at 10
 3 M.1 7 b-oestradiol tested at
concentrations ranging from 10
 12 to 10
 8 M produced a typical
sigmoid dose–response curve with a maximal response similar to
the one observed for clodronate but occurring at a much lower
concentrations. The EC50 values (concentrations leading to half
maximal stimulation) were around 6 10
 5 and 2 10
 12M for
clodronate and E2, respectively. Of note, because of the higher doses
that were required, no true plateau phase was reached for clodronate.
However, by analogy with the dose–response curve obtained with
E2, the two-fold stimulation of growth induced by 10
 3 M clodronate
in MCF-7 cells was considered as the maximum effect.
Moreover, we obtained closely similar findings using IBEP-2 cell
line, which has recently been reported as an oestrogen-responsive
cell line closely resembling the MCF-7 cell line (Journe et al,
2004a). We indeed showed that clodronate as well as E2 stimulated
the proliferation of IBEP-2 cells cultured in SFM (Figure 3, middle
panel), indicating that the mitogenic stimulation induced by the
bisphosphonate was not restricted to the MCF-7 cells. By contrast,
clodronate weakly inhibited the proliferation of MDA-MB-231 cells
which are ER-negative breast cancer cells, thus nonsensitive to E2
stimulation (Figure 3, bottom panel). Altogether, these data
suggest that ER status may be important in the mitogenic effects
of clodronate.
Suppression of clodronate-induced MCF-7 cells growth by
antioestrogens
As suggested above (see Figures 1 and 3), the ER pathway was
somehow involved in the mitogenic effect of clodronate. We tested
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Figure 1 Clodronate stimulated MCF-7 cell proliferation in SFM but not
in complete medium. Cancer cells were incubated for 72h with 10
 4 M
clodronate (Clod), 10
 9 M E2 or vehicle (control) in complete medium or
SFM. Cell proliferation was determined by crystal violet staining assay
(optical density for control value was 2.129 in complete medium, and 1.197
in SFM). Data are presented as percentages of control values (mean7s.d.).
Mean of results is pooled from four experiments (n¼24). *ANOVA,
Po0.05 vs control.
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Figure 2 Time-course experiments. Cells were cultured for up to 3 days
in SFM containing 10
 4 M clodronate (circle), 10
 9 M E2 (square) or vehicle
(control, triangle). Measurement was performed as described in Figure 1.
*ANOVA, Po0.05 vs control.
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antioestrogen 4-OH-TAM and the pure antioestrogen fulvestrant
(ICI 182,780). IN SFM, exposure of MCF-7 cells to 10
 7 M
antioestrogen for 72h reduced cell populations by 2079%
(mean7s.d., Po0.05) (4-OH-TAM) and by 4076% (Po0.05)
(fulvestrant) (Figure 4). This ability of antioestrogens to impede
the growth of ER-positive breast cancer cells (either by interfering
with cell proliferation and/or by inducing cell apoptosis) even in
the absence of oestrogenic stimulation has also been found by
other investigators (Jensen et al, 2003). Simultaneous addition of
partial or pure antioestrogen with clodronate completely abolished
the mitogenic effects of the bisphosphonate and decreased cell
growth to values similar to those observed in the presence of
antioestrogen alone. As expected, the proliferative response to
10
 10 M E2 was similarly suppressed by concomitant addition of
4-OH-TAM or fulvestrant (Figure 4). Interestingly, previous
exposure of MCF-7 cells to antioestrogen for 8h prior to treatment
with clodronate was as efficient as the addition of antioestrogen in
combination with clodronate in suppressing the mitogenic effect of
the latter (data not shown). These data suggest that preliminary
blockade of ER-mediated signalling was sufficient to suppress
clodronate-induced cell proliferation, and indicate that clodronate
may indeed act through the ER pathway.
Oestrogenic effects of clodronate in SFM: downregulation
of oestrogen receptor, induction of progesterone receptor
and transactivation of an oestrogen-responsive reporter
gene
As suggested by the use of antioestrogens (see Figure 4),
the mitogenic action of clodronate might be mediated by ER.
This led us to investigate ER expression and activity under
clodronate exposure.
We determined the effect of clodronate on ER expression by
Western blot analysis using an antibody raised against the F
domain of the receptor (Figure 5). The amount of immunoreactive
ER was determined in MCF-7 cells after 24h of treatment with
clodronate and/or E2 in SFM. Densitometric analysis allowed
semiquantitative evaluation of ER protein changes. We found that
10
 4 M clodronate decreased ER amount by about 50%. As
expected, 10
 9 M E2 led to a more drastic downregulation of the
ER protein. Interestingly, the combination of clodronate and E2
induced a complete disappearance of the receptor, suggesting that
both compounds may produce additive effects on ER down-
regulation (Figure 5), and that the pathway for ER downregulation
differs according to the drug.
We then investigated if clodronate could induce ER-mediated
gene transactivation. The effect of clodronate on the oestrogen-
inducible PgR gene was assessed by Western blot analysis using an
antibody raised against the A/B isoforms of human PgR. Exposure
of MCF-7 cells for 72h to 10
 4 M clodronate in SFM doubled the
expression of PgR-B isoform (114kDa, the isoform known to
function as a transcriptional activator) (Figure 6). This induction
was much less than the one observed with 10
 9 M E2, which
increased the PgR level by more than six-fold. The combination of
clodronate and E2 did not further increase the amount of PgR
(possible upper limit with this method beyond which no further
increase in protein level can be documented). In control
conditions, the A isoform of PgR (94kDa, the isoform known to
act as a transcriptional inhibitor) was not detectable in MCF-7
cells. Small amounts of the A isoform were observed after
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Figure 3 Dose-dependent effects of 17b-oestradiol and clodronate on
the proliferation of MCF-7, IBEP-2 and MDA-MB-231 cells. Breast cancer
cells were treated for 72h with increasing concentrations of E2 (10
 12–
10
 8 M), clodronate (Clod) (10
 7–10
 3 M) or vehicle (control) in SFM.
The rest is the same as in Figure 1. *ANOVA, Po0.05 vs control.
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Figure 4 Clodronate-induced cell growth was suppressed by antioes-
trogens. MCF-7 cells were exposed for 3 days to 10
 4 M clodronate (Clod),
10
 10 M E2,1 0
 7 M 4-OH-TAM (TAM), 10
 7 M fulvestrant (ICI) or vehicle
(control) in SFM. The rest is the same as in Figure 1. *ANOVA, Po0.05 vs
control.
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effect on PgR-A expression. The B/A ratios determined for
clodronate- and E2-induced stimulation were, however, similar
(averaging 15), suggesting no difference in ER-mediated gene
transactivation.
Finally, the transcriptional activity of ER was investigated in
MVLN cells obtained by stable transfection of MCF-7 cells with an
oestrogen-responsive luciferase reporter gene. Culture for 24h in
SFM containing 10
 4 M clodronate resulted in a significant increase
in ER-induced luciferase expression by 106756% (mean7s.d.,
Po0.05) (Figure 7). Reporter gene transactivation caused by
10
 9 M E2 was stronger (279764%, Po0.05). The activation of the
reporter gene was further increased when clodronate and E2 were
combined (4317106%, Po0.05). The stimulation of luciferase
activity by clodronate and E2 were both completely abrogated by
simultaneous incubation with 4-OH-TAM or fulvestrant, again
suggesting that Clod may specifically induce ER activation.
DISCUSSION
Bisphosphonates, including clodronate, are widely used for the
treatment of metastatic bone disease (Body et al, 1998; Lipton,
2003). In particular, they are administered to alleviate skeletal
complications resulting from osteoclast-mediated tumour bone
disease associated with breast and prostate cancers, and multiple
myeloma. Although human data are still scarce, a double-blind
trial involving more than 1000 breast cancer cases after surgery
indicates that a 2-year treatment with clodronate can reduce the
incidence of bone metastases by about one-half, and prolong
patient survival (Powles et al, 2002).
Bisphosphonates are also currently evaluated in combination
with third-generation AIs (Coleman, 2003), which appear to be
more efficient than tamoxifen as a first-line treatment of advanced
breast cancer (Bonneterre et al, 2000; Nabholtz et al, 2000;
Mouridsen et al, 2001), as well as in the adjuvant setting (Baum
et al, 2002). Thus, the administration of bisphosphonates, notably
clodronate, in combination with AIs seems to be an attractive
choice in order to prevent the risk of bone loss associated with
complete oestrogen deprivation therapy, with the additional
possibility of simultaneously decreasing the incidence of bone
metastases (Cummings et al, 1998).
In our study, we investigated the effects of clodronate on
the proliferation of MCF-7 cells cultured in SFM, an in vitro
model that mimics breast tumours exposed to treatment combin-
ing the bisphosphonate clodronate and AI-induced oestrogen
deprivation. Quite surprisingly, we found that clodronate stimu-
lated the proliferation of MCF-7 cells in these particular
conditions. Moreover, in the same conditions, clodronate
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Figure 5 Clodronate downregulated oestrogen receptor expression as
assessed by Western blot. MCF-7 cells were incubated for 24h with
10
 4 M clodronate (Clod), 10
 9 M E2, ClodþE2 or vehicle (control) in SFM.
Equal quantities of proteins (20mg) were subjected to 10% SDS–PAGE
and electrotransferred onto nitrocellulose membranes. Immunodetection
was performed with anti-human ER antibody raised against its F domain.
Blots show representative experiments performed twice. Quantitative data
were obtained from densitometric analyses and are presented as
percentages of control values (mean). ND¼not detectable.
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Figure 6 Clodronate induced progesterone receptor expression as
determined using Western blot. MCF-7 cells were incubated for 72h in
SFM containing 10
 4 M clodronate (Clod), 10
 9 M E2, ClodþE2 or vehicle
(control). Equal amounts of proteins (40mg) were subjected to 8% SDS–
PAGE and electrotransferred onto nitrocellulose membranes. Immunode-
tection was assessed with anti-human PgR antibody raised against A/B
isoforms of the receptor. Blots show representative experiments
performed twice. Quantitative data were obtained from densitometric
analyses of the B-isoform and are presented as percentages of control
values (mean).
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ER, the expression of progesterone receptor and the transactiva-
tion of a reporter gene. Hence, clodronate might increase MCF-7
cell proliferation through specific ER activation, as suggested by a
complete suppression of its mitogenic effects by partial or pure
antioestrogens.
The concentration of clodronate (10
 4 M) that was needed to
stimulate the growth of MCF-7 cells in SFM appears to be at least
10-fold higher than the circulatory levels in patients treated with
bisphosphonates (Osterman and Lauren, 1991; Villikka et al,
2002). Nevertheless, it has been shown that bisphosphonates
accumulate in bone (Lin et al, 1992), and that their effective local
concentrations at sites of active bone resorption are much higher
than serum levels, and may reach up to 10
 3 M in the resorption
lacunae (Sato et al, 1991). It is unclear whether the bioavailability
of bone bisphosphonates for cancer cells would result in effective
concentration as high as 10
 4 M. However, we can speculate that
the close association of breast cancer cells in chronically treated
patients with actively resorbing osteoclasts within lytic lesions will
result in exposure of the tumor cells to high levels of bispho-
sphonates. Therefore, it is likely that metastatic tumor cells in
patients could be exposed to high doses of clodronate for long
periods of time.
This is the first time that clodronate is reported to exert a
significant proliferative action on MCF-7 breast cancer cells
cultured in SFM for 2 or 3 days. Previous studies examining the
influence of clodronate on MCF-7 cell growth have shown either
no effect, a modest inhibition of cell growth after short exposure in
serum-free medium or a moderate one after high-dose exposure or
prolonged treatment (more than 6 days) in serum-containing
medium (Busch et al, 1998; Fromigue et al, 2000; Senaratne et al,
2000). The weak proapoptotic effects of clodronate that has been
occasionally observed could be attributed to the accumulation of
toxic analogues of ATP generated by bisphosphonate metabolism
(Frith et al, 1997). By contrast, in our study, clodronate showed no
effect on cells grown in medium containing complete serum,
suggesting that serum growth factors may prevent clodronate-
induced apoptosis, and that serum steroids may obscure
clodronate-induced cell growth.
Importantly, the oestrogenic stimulation induced by clodronate
was not cell line specific. In SFM, we indeed obtained similar
results using the IBEP-2 cell line which was previously established
in our laboratory from breast carcinoma (Siwek et al, 1998). IBEP-
2 cells have recently been characterised as an oestrogen-responsive
cell line closely resembling the MCF-7 cells with regard to ER
expression, cell mitogenic response to oestrogenic stimulation and
sensitivity to antioestrogens (Journe et al, 2004a). We thus
observed that clodronate stimulated IBEP-2 cell proliferation,
and also provoked ER downregulation and induced PgR expres-
sion (two last data not shown). By contrast, the MDA-MD-231
cells, which do not express functional ER, exhibited no oestrogenic
response to the bisphosphonate in SFM. Furthermore, at the
highest concentration, clodronate inhibited MDA-MB-231 cell
growth, probably because of the accumulation of nonhydrolysable
analogues of ATP. Consequently, it appears that the mitogenic
actions of clodronate can only be detected in oestrogen-responsive
breast cancer cells cultured in SFM, the sole conditions appro-
priate for the observation of E2-induced stimulation.
Clodronate belongs to the group of non-nitrogen bispho-
sphonates closely resembling pyrophosphate. As mentioned above,
it can be metabolised to nonhydrolysable analogues of ATP
affecting numerous biosynthetic, metabolic or signal transduction
pathways involving the hydrolysis or synthesis of ATP, including
DNA synthesis, glycolysis and protein phosphorylation (Frith et al,
1997). Accumulation of toxic ATP analogues could account for the
weak toxicity of clodronate reported in previous studies (Fromigue
et al, 2000; Senaratne et al, 2000). However, in SFM, it is likely that
the weak toxicity of nonhydrolysable ATP analogues may be
masked by the oestrogenic effect of clodronate, as we describe in
oestrogen-sensitive cell lines. The molecular mechanisms by which
clodronate stimulates MCF-7 cell growth through ER activation in
SFM remain a matter of speculation. Direct interaction of
clodronate with ER, leading to the activation of the receptor, is
conceivable. Indeed, pyrophosphate has been reported to enhance
E2-mediated binding of rat uterine ER to oligodeoxythymidylate
cellulose (Myatt et al, 1985). On the other hand, because of its close
structural similarity with pyrophosphate, clodronate could alter
intracellular processes involving protein phosphorylation/depho-
sphorylation. An attractive possibility would be that clodronate
interferes with the activity of phosphatases similar to alendronate
or tiludronate in osteoclasts (Schmidt et al, 1996; Murakami et al,
1997), and causes subsequent accumulation of phosphorylated key
proteins implicated in mitogenic signaling pathways such as ERK1/
2. Supporting this view, pervanadate, a potent inhibitor of tyrosine
phosphatases, was reported to activate ERK1/2 (Zhao et al, 1996),
and etidronate, another pyrophosphate-like bisphosphonate, has
been reported to produce a rapid and transient increase in the
phosphorylation of ERK1/2 (Plotkin et al, 1999). Hence, clodronate
could act as a phosphatase inhibitor promoting ERK1/2 phosphor-
ylation, which in turn could activate ER and stimulate its binding
to DNA (at ERE and/or AP-1 sites), inducing gene transcription
and further cell proliferation (Kushner et al, 2000). Of note, several
lines of evidence indicate that E2 can also increase ERK1/2
phosphorylation in MCF-7 cells, thereby promoting cell growth
through the activation of the MAPK pathway (Improta-Brears et al,
1999; Driggers and Segars, 2002). Further experiments are
warranted to confirm this hypothesis.
By contrast, nitrogen-containing bisphosphonates (e.g. pami-
dronate, ibandronate and zoledronic acid) exhibit cytotoxic effects
by interfering with the mevalonate pathway, leading to inhibition
of the post-translational prenylation of small GTP-binding
proteins such as Ras, that are necessary for cell function and
survival (Luckman et al, 1998; Russell and Rogers, 1999). The
antitumoral activity of nitrogen-containing bisphosphonates on
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Clod+E 2
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Figure 7 Clodronate stimulated ER transcriptional activity. MVLN cells
were incubated in SFM for 24h with 10
 4 M clodronate (Clod), 10
 10 M E2,
10
 7 M 4-OH-TAM (TAM), 10
 7 M fulvestrant (ICI), combination of Clod
or E2 with antioestrogens, ClodþE2 or vehicle (control) in SFM. Luciferase
activities were normalised with protein levels. Data are given as
percentages of control values (mean7s.d.). Experiments were performed
four times in replicate (n¼8). *ANOVA, Po0.05 vs control.
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associated with induction of apoptosis (Fromigue et al, 2000;
Senaratne et al, 2000; Jagdev et al, 2001). Differences between
clodronate and nitrogen-containing bisphosphonate actions were
also observed in steroid-free culture conditions since 10
 4 M
ibandronate strongly inhibited MCF-7 cell growth (IC50¼10
 4 M)
and did not affect ER expression or activity (Journe et al, 2004b).
In conclusion, we report a previously unknown mitogenic effect
of the bisphosphonate clodronate on MCF-7 breast cancer cells
cultured in SFM, an environment mimicking that created by the
administration of AIs in vivo. Even though obtained by in vitro
studies, our observations raise the possibility of growth stimula-
tion of ER-positive breast cancer in patients receiving AIs and
clodronate, a combined therapy that will probably be used
extensively in future. Our data thus suggest that caution has to
be exercised before extensive combined clinical use of AIs with
clodronate. Further experimental work must, however, be under-
taken to establish the relevance of our in vitro observations.
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